- Lifetime QALY prioritarianism in priority setting.Trygve Ottersen - 2013 - Journal of Medical Ethics 39 (3):175-180.details
|
|
Saving lives, moral theory, and the claims of individuals.Michael Otsuka - 2006 - Philosophy and Public Affairs 34 (2):109–135.details
|
|
Toward a Broader View of Values in Cost‐Effectiveness Analysis of Health.Paul Menzel, Marthe R. Gold, Erik Nord, Jose-Louis Pinto-Prades, Jeff Richardson & Peter Ubel - 1999 - Hastings Center Report 29 (3):7-15.details
|
|
For the Sake of Justice: Should We Prioritize Rare Diseases?Niklas Juth - 2017 - Health Care Analysis 25 (1):1-20.details
|
|
Should we accept a higher cost per health improvement for orphan drugs? A review and analysis of egalitarian arguments.Niklas Juth, Martin Henriksson, Erik Gustavsson & Lars Sandman - 2020 - Bioethics 35 (4):307-314.details
|
|
The significance of ‘severity’.Daniel Hausman - 2019 - Journal of Medical Ethics 45 (8):545-551.details
|
|
Hope or despair: a response to ‘Do not despair about severity—yet’.Daniel Hausman - 2020 - Journal of Medical Ethics 46 (8):559-559.details
|
|
Ethical issues in funding orphan drug research and development.C. A. Gericke - 2005 - Journal of Medical Ethics 31 (3):164-168.details
|
|
Severity as a Priority Setting Criterion: Setting a Challenging Research Agenda.Mathias Barra, Mari Broqvist, Erik Gustavsson, Martin Henriksson, Niklas Juth, Lars Sandman & Carl Tollef Solberg - 2019 - Health Care Analysis 28 (1):25-44.details
|
|
Do not despair about severity—yet.Mathias Barra, Mari Broqvist, Erik Gustavsson, Martin Henriksson, Niklas Juth, Lars Sandman & Carl Tollef Solberg - 2020 - Journal of Medical Ethics 46 (8):557-558.details
|
|
Rare diseases in healthcare priority setting: should rarity matter?Andreas Albertsen - 2022 - Journal of Medical Ethics 48 (9):624-628.details
|
|